Abstract
The purpose of this article is to study biopharmaceutical innovation ecosystems through the prism of the results of intellectual activity and objects of civil and business turnover. In doing so, this work aims to answer the following research question: which stakeholders are needed for innovation systems in the biopharmaceutical industry and what is their main role in creating intellectual property. The research strategy was developed in accordance with the grounded theory methodology. The author makes an attempt to prove that biopharmaceutical innovation ecosystems consist of a multi-level set of key stakeholders. In addition, taking a holistic view of biopharma innovation ecosystems, the study traces the dynamics of biopharma innovation ecosystems through a driving force analysis. This article presents an attempt to deeply analyze biopharmaceutical innovation ecosystems from a holistic perspective, including regulatory issues. The conclusions made in the article can be considered an important addition to biopharmaceutical innovations around the world.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Courier of Kutafin Moscow State Law University (MSAL))
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
